At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Atalurendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Non-Interventional, Clinical Study to Assess Dystrophin Levels in Subjects With Nonsense Mutation Duchenne Muscular Dystrophy Who Have Been Treated With Ataluren for ≥9 Months
In Brief
A Phase 2 clinical trial evaluating Ataluren for Duchenne Muscular Dystrophy. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study is designed to generate additional data on the effect of ataluren for producing dystrophin protein in nonsense mutation nmDMD participants. This study will evaluate dystrophin levels from participants with nmDMD who currently have been receiving ataluren for ≥9 months. The study will have a single visit (Visit 1).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuchenne Muscular Dystrophy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartApr 2019
Primary CompletionJun 2019
TodayJul 2026
First PostedJan 8, 2019
Enrollment StartApr 11, 2019
Primary CompletionJun 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.5 years ago
Interventions
Atalurendrug
Ataluren will be administered as per the dose and schedule specified in the arm.